课题基金 / 基金详情

A novel enzymatic activity of WSTF and its role in tumorigenesis

A novel enzymatic activity of WSTF and its role in tumorigenesis
WSTF 的新酶活性及其在肿瘤发生中的作用
批准号:
8122501
负责人:
zhuo Andrew Xiao
金额:
$24.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2013-06-30
关键词:

项目摘要

项目成果

zhuo Andrew Xiao的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
My long term research Interest is to investigate epigenetic mechanisms to suppress tumorigenesis. Recent studies suggest that the DNA damage response (DDR) induced by aberrant proliferation, may be one of the barriers at early stage of tumorigenesis to prevent genomic instability. One hallmark of DDR at early stage of tumorigenesis Is histone H2A.X S139 phosphorylation (known as H2A.X). This phosphorylation event is well-known for its demarcation of compact chromatin structures formed during DDR induced by DNA damage agents. In keep with these observations, H2A.X deficiency accelerates the tumor progression on a p53 deficient background in mice. Our preliminary studies have identified a new mark phosphorylation on H2A.X, tyrosine 142 and its kinase, WSTF (William-Beuren Syndrome Transcription Factor), a gene frequently deleted In human William-Beuren Syndrome (WS). Our studies have demonstrated that WSTF has an intrinsic tyrosine kinase activity via its unconventional kinase domain, which shares no homology with any known kinase fold. Interestingly, our recent data indicate that the WSTF and ATM may form a "feed-forward" loop to regulate DDR induced by DNA damage treatment, including H2A.X (S139) phosphorylation. WSTF may also play a critical role in DDR initiated by aberrant proliferation; therefore, it may suppress tumorigenesis by preventing genomic instability. In the mentored phase, I will test if WSTF function is regulated by the ATM/R kinases. A parallel objective in this phase is to develop H2A.X "designer chromatin" in collaboration with Dr. Tom Muir's lab (Rockefeller University). In the independent phase, I will test WSTF function for suppressing tumorigenesis in genetically modified mouse models. The goal of the mentored phase (I year) is to develop key methodologies and reagents for the independent phase and beyond. At the same time, I will apply for independent positions. The excellent environment in Drs. Allis and Muir's lab will facilitate my research in the mentored phase and my transition to an independent investigator. The proposed research at the independent phase (3 years) will pave the road to launch my future investigations to Identify novel epigenetic mechanisms to suppress tumorigenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel epigenetic mechanism in early embryogenesis
  • 批准号:
    10799233
  • 项目类别:
  • 资助金额:
    $19.39万
  • 财政年份:
    2020
  • 负责人:
    zhuo Andrew Xiao
  • 依托单位:
A novel epigenetic mechanism in early embryogenesis
  • 批准号:
    10369001
  • 项目类别:
  • 资助金额:
    $46.0万
  • 财政年份:
    2020
  • 负责人:
    zhuo Andrew Xiao
  • 依托单位:
A novel epigenetic mechanism in early embryogenesis
  • 批准号:
    10584485
  • 项目类别:
  • 资助金额:
    $46.0万
  • 财政年份:
    2020
  • 负责人:
    zhuo Andrew Xiao
  • 依托单位:
Investigate Novel Epigenetic Silencing Mechanisms in Mouse ESCs
  • 批准号:
    9034611
  • 项目类别:
  • 资助金额:
    $41.65万
  • 财政年份:
    2015
  • 负责人:
    zhuo Andrew Xiao
  • 依托单位:
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: